Good news on a H5N1 vaccine efficacy in a preclinical model in case it is needed
science.org/doi/10.1126/...
science.org/doi/10.1126/...
December 18, 2024 at 7:10 PM
Good news on a H5N1 vaccine efficacy in a preclinical model in case it is needed
science.org/doi/10.1126/...
science.org/doi/10.1126/...
GOOD NEWS! Researchers at the University of Buffalo have developed a nanoparticle-based vaccine candidate for H5N1 avian influenza (clade 2.3.4.4b) that achieved 100% PROTECTION in preclinical trials. The vaccine is under development for potential use in BOTH veterinary AND human medicine. 🧪🧵⬇️
April 22, 2025 at 4:00 PM
GOOD NEWS! Researchers at the University of Buffalo have developed a nanoparticle-based vaccine candidate for H5N1 avian influenza (clade 2.3.4.4b) that achieved 100% PROTECTION in preclinical trials. The vaccine is under development for potential use in BOTH veterinary AND human medicine. 🧪🧵⬇️
THIS IS HUGE! MIT researchers have developed dual-therapy microparticles that can deliver chemotherapy AND phototherapy WITHOUT harsh side effects. Preclinical studies show this approach completely eradicated tumors AND extended survival more than single treatments alone. Let’s talk about that! 🧪🧵⬇️
December 24, 2024 at 5:00 PM
THIS IS HUGE! MIT researchers have developed dual-therapy microparticles that can deliver chemotherapy AND phototherapy WITHOUT harsh side effects. Preclinical studies show this approach completely eradicated tumors AND extended survival more than single treatments alone. Let’s talk about that! 🧪🧵⬇️
GOOD NEWS! Researchers at the University of New Mexico have developed a tau-targeting vaccine that could help PREVENT the progression of Alzheimer’s disease. In preclinical trials, the vaccine REDUCED pTau, IMPROVED memory AND motor function, and REDUCED brain atrophy with NO major side effects. 🧪🧵⬇️
May 5, 2025 at 4:00 PM
GOOD NEWS! Researchers at the University of New Mexico have developed a tau-targeting vaccine that could help PREVENT the progression of Alzheimer’s disease. In preclinical trials, the vaccine REDUCED pTau, IMPROVED memory AND motor function, and REDUCED brain atrophy with NO major side effects. 🧪🧵⬇️
THIS IS HUGE! Researchers at the University of Pennsylvania have developed a vaccine against the bacterium Clostridioides difficile (C.diff), that in preclinical studies, protected against succumbing from infection AND prevented recurring cases. Let’s talk about that! 🧪🧵⬇️
October 9, 2024 at 4:00 PM
THIS IS HUGE! Researchers at the University of Pennsylvania have developed a vaccine against the bacterium Clostridioides difficile (C.diff), that in preclinical studies, protected against succumbing from infection AND prevented recurring cases. Let’s talk about that! 🧪🧵⬇️
“I am shocked and appalled,” one NCI scientist said. “We are moving funds away from so much promising research in order to do a preclinical study based on nonscientific ideas. It’s absurd.”
Holy shit—a terrible waste of $$
Bhattacharya is so kooky
“If lots of people believe it & it’s moving public health, we as NIH have an obligation, again, to treat it seriously,” Bhattacharya said at a MAHA event
Great reporting by @rachanadpradhan.bsky.social
kffhealthnews.org/news/article...
Bhattacharya is so kooky
“If lots of people believe it & it’s moving public health, we as NIH have an obligation, again, to treat it seriously,” Bhattacharya said at a MAHA event
Great reporting by @rachanadpradhan.bsky.social
kffhealthnews.org/news/article...
US Cancer Institute Studying Ivermectin’s ‘Ability To Kill Cancer Cells’ - KFF Health News
At a January event organized by allies of health secretary Robert F. Kennedy Jr., National Cancer Institute Director Anthony Letai said results may be released “in a few months.” Ivermectin, used to d...
kffhealthnews.org
February 10, 2026 at 2:16 PM
“I am shocked and appalled,” one NCI scientist said. “We are moving funds away from so much promising research in order to do a preclinical study based on nonscientific ideas. It’s absurd.”
THIS IS HUGE! Researchers at Harvard Medical School have developed a nasal spray that in preclinical studies, offered NEARLY 100% protection from respiratory infections by COVID-19, influenza, viruses, AND pneumonia-causing bacteria. Let’s talk about that! 🧪🧵⬇️
September 29, 2024 at 8:00 PM
THIS IS HUGE! Researchers at Harvard Medical School have developed a nasal spray that in preclinical studies, offered NEARLY 100% protection from respiratory infections by COVID-19, influenza, viruses, AND pneumonia-causing bacteria. Let’s talk about that! 🧪🧵⬇️
THIS IS HUGE! Researchers at JHU have developed an experimental drug called RK-33, that in preclinical studies has shown promise in treating breast cancer with bone metastases. RK-33 eliminated the metastases AND prevented further cancer spread. Let’s talk about that! 🧪🧵⬇️
October 21, 2024 at 4:00 PM
THIS IS HUGE! Researchers at JHU have developed an experimental drug called RK-33, that in preclinical studies has shown promise in treating breast cancer with bone metastases. RK-33 eliminated the metastases AND prevented further cancer spread. Let’s talk about that! 🧪🧵⬇️
p-tau 217 as a stand-alone blood marker establishes risk of Alzheimer's disease in cognitively unimpaired individuals (again)
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Plasma P-Tau217 to Identify Preclinical AD
This cohort study evaluates the use of plasma phosphorylated tau 217 in identifying preclinical Alzheimer disease in individuals with amyloid β pathology.
jamanetwork.com
September 15, 2025 at 4:28 PM
p-tau 217 as a stand-alone blood marker establishes risk of Alzheimer's disease in cognitively unimpaired individuals (again)
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
We know GLP-1 drugs reduce brain inflammation. But I didn't anticipate bipolar disorder as a possible indication in the future
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Glucagon-like Peptide-1 receptor agonists as emerging therapeutics in bipolar disorder: a narrative review of preclinical and clinical evidence - Molecular Psychiatry
Molecular Psychiatry - Glucagon-like Peptide-1 receptor agonists as emerging therapeutics in bipolar disorder: a narrative review of preclinical and clinical evidence
www.nature.com
September 13, 2025 at 7:20 PM
We know GLP-1 drugs reduce brain inflammation. But I didn't anticipate bipolar disorder as a possible indication in the future
www.nature.com/articles/s41...
www.nature.com/articles/s41...
THIS IS HUGE! Researchers at Lancaster University have developed RI-AG03, a peptide inhibitor, that in preclinical studies PREVENTED the build-up of harmful Tau proteins in the brain, which are believed to be a key driver of Alzheimer’s disease. Let’s talk about that! 🧪🧵⬇️
October 17, 2024 at 4:00 PM
THIS IS HUGE! Researchers at Lancaster University have developed RI-AG03, a peptide inhibitor, that in preclinical studies PREVENTED the build-up of harmful Tau proteins in the brain, which are believed to be a key driver of Alzheimer’s disease. Let’s talk about that! 🧪🧵⬇️
Amazing news!
This is why you don’t cut cancer research funding…
On the verge of a major cancer treatment breakthrough, with a new vaccine shown to completely obliterate pancreatic cancer cells in preclinical trials. Paves the way for move onto the human trial stage.
newatlas.com/cancer/pancr...
This is why you don’t cut cancer research funding…
On the verge of a major cancer treatment breakthrough, with a new vaccine shown to completely obliterate pancreatic cancer cells in preclinical trials. Paves the way for move onto the human trial stage.
newatlas.com/cancer/pancr...
Pancreatic cancer vaccine eradicates trace of disease in early trials
We could be on the verge of a major cancer treatment breakthrough, with a new vaccine shown to completely obliterate pancreatic cancer cells in preclinical trials. This paves the way for it to move on...
newatlas.com
June 13, 2025 at 1:34 AM
Amazing news!
This is why you don’t cut cancer research funding…
On the verge of a major cancer treatment breakthrough, with a new vaccine shown to completely obliterate pancreatic cancer cells in preclinical trials. Paves the way for move onto the human trial stage.
newatlas.com/cancer/pancr...
This is why you don’t cut cancer research funding…
On the verge of a major cancer treatment breakthrough, with a new vaccine shown to completely obliterate pancreatic cancer cells in preclinical trials. Paves the way for move onto the human trial stage.
newatlas.com/cancer/pancr...
WOW! Researchers at ETH Zurich have effectively suppressed the growth of Glioblastoma, the most aggressive and deadly brain cancer, in BOTH ex vivo human tissue samples AND in preclinical trials with Vortioxetine- an FDA APPROVED serotonin modulator.
Let’s talk about that! 🧪🧵⬇️
Let’s talk about that! 🧪🧵⬇️
October 3, 2024 at 4:00 PM
WOW! Researchers at ETH Zurich have effectively suppressed the growth of Glioblastoma, the most aggressive and deadly brain cancer, in BOTH ex vivo human tissue samples AND in preclinical trials with Vortioxetine- an FDA APPROVED serotonin modulator.
Let’s talk about that! 🧪🧵⬇️
Let’s talk about that! 🧪🧵⬇️
You have to start somewhere. Preclinical trials are always usually in an animal model.
October 9, 2024 at 4:05 PM
You have to start somewhere. Preclinical trials are always usually in an animal model.
This is still preclinical. bsky.app/profile/sail...
So that depends on a lot of factors. Funding, resources, etc. However, what does stand out about this is that if this technology/method could easily be adapted for current manufacturers it could speed up the process.
January 2, 2025 at 7:49 PM
This is still preclinical. bsky.app/profile/sail...
vaccine that targets BOTH the viruses AND the sugars they use to avoid detection. In preclinical studies, the vaccine REMOVED these sugar molecules from a stable region of the coronavirus spike protein, helping the immune system produce strong and effective antibodies to neutralize the virus.
March 27, 2025 at 4:04 PM
vaccine that targets BOTH the viruses AND the sugars they use to avoid detection. In preclinical studies, the vaccine REMOVED these sugar molecules from a stable region of the coronavirus spike protein, helping the immune system produce strong and effective antibodies to neutralize the virus.
Covid mRNA vaccines have a rare link to myocarditis adverse events (~30 cases per million 2nd doses).
Extensive work in mice shows two inflammation mediators that appear to be the mediators and a plant-derived anti-inflammatory (genistein) that blocks it
www.science.org/doi/10.1126/...
Extensive work in mice shows two inflammation mediators that appear to be the mediators and a plant-derived anti-inflammatory (genistein) that blocks it
www.science.org/doi/10.1126/...
Inhibition of CXCL10 and IFN-γ ameliorates myocarditis in preclinical models of SARS-CoV-2 mRNA vaccination
Preclinical models of SARS-CoV-2 vaccination revealed a targetable CXCL10–IFN-γ axis that drives cytokine-induced cardiac injury.
www.science.org
December 10, 2025 at 7:07 PM
Covid mRNA vaccines have a rare link to myocarditis adverse events (~30 cases per million 2nd doses).
Extensive work in mice shows two inflammation mediators that appear to be the mediators and a plant-derived anti-inflammatory (genistein) that blocks it
www.science.org/doi/10.1126/...
Extensive work in mice shows two inflammation mediators that appear to be the mediators and a plant-derived anti-inflammatory (genistein) that blocks it
www.science.org/doi/10.1126/...
🌿 CBD mitigated alcohol intake, prevented alcohol-induced damage to the brain, and attenuated relapse-like behaviors in preclinical research. #NORML #cannabis #marijuana #CBD #alcohol
CBD Reduces Cravings for Alcohol
Preclinical data published in the journal Nature: Neuropsychopharmacology
norml.org
August 20, 2025 at 5:35 PM
🌿 CBD mitigated alcohol intake, prevented alcohol-induced damage to the brain, and attenuated relapse-like behaviors in preclinical research. #NORML #cannabis #marijuana #CBD #alcohol
In preclinical studies with hamsters and mice, the universal vaccine created MORE diverse antibodies with HIGHER titers (concentrations in the blood, where immune system cells travel throughout the body) compared to individual vaccines against variants of SARS-CoV, as well as MERS-CoV, the virus
March 27, 2025 at 4:07 PM
In preclinical studies with hamsters and mice, the universal vaccine created MORE diverse antibodies with HIGHER titers (concentrations in the blood, where immune system cells travel throughout the body) compared to individual vaccines against variants of SARS-CoV, as well as MERS-CoV, the virus
A schematic of the mechanism of the CHIP-protective variant. MSI2 is a drug target for prevention of cancer in preclinical testing science.org/doi/10.1126/...
January 1, 2026 at 7:05 PM
A schematic of the mechanism of the CHIP-protective variant. MSI2 is a drug target for prevention of cancer in preclinical testing science.org/doi/10.1126/...
This is a PRECISION weapon. A living, self-regulating machine that targets only the tumor's environment and ignores healthy tissue.
The team is now heading into preclinical trials and testing it on real tumors.
We are watching history happen.
The team is now heading into preclinical trials and testing it on real tumors.
We are watching history happen.
April 9, 2026 at 12:07 AM
This is a PRECISION weapon. A living, self-regulating machine that targets only the tumor's environment and ignores healthy tissue.
The team is now heading into preclinical trials and testing it on real tumors.
We are watching history happen.
The team is now heading into preclinical trials and testing it on real tumors.
We are watching history happen.
This is Profi btw.
A Drug-Free Nasal Spray May Shield Against Respiratory Infections
Gel-like coating wards off cold viruses, flu, and more in preclinical studies
hms.harvard.edu
December 23, 2024 at 7:20 PM
This is Profi btw.
Preclinical getting ready to move into human trials. bsky.app/profile/sail...
October 12, 2025 at 4:04 PM
Preclinical getting ready to move into human trials. bsky.app/profile/sail...
The next phase of the research will focus on advancing the most promising compounds into clinical trials. The researchers anticipate Phase I trials beginning in 2028 after completing preclinical development. Since glycans have also been implicated in cancer and immune disorders,
April 17, 2026 at 4:13 PM
The next phase of the research will focus on advancing the most promising compounds into clinical trials. The researchers anticipate Phase I trials beginning in 2028 after completing preclinical development. Since glycans have also been implicated in cancer and immune disorders,
This is AMAZING. Researchers at City of Hope have developed an investigational small molecule therapeutic that appears to annihilate ALL solid tumors (across 70 evaluated cancer types) in preclinical research. Phase 1 clinical trials ARE underway! Let’s talk about that! 🧵⬇️🧪
August 3, 2023 at 4:23 PM
This is AMAZING. Researchers at City of Hope have developed an investigational small molecule therapeutic that appears to annihilate ALL solid tumors (across 70 evaluated cancer types) in preclinical research. Phase 1 clinical trials ARE underway! Let’s talk about that! 🧵⬇️🧪